Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:

Citi’s 2025 Global Healthcare Conference
Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET

Evercore 8th Annual Healthcare Conference 
Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET

The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Investor Contact: 
Eva Stroynowski
ir@apellis.com
617.938.6229


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  198.86
-5.22 (-2.56%)
AAPL  269.42
-6.08 (-2.21%)
AMD  210.85
-2.73 (-1.28%)
BAC  52.77
-1.09 (-2.01%)
GOOG  310.80
-0.53 (-0.17%)
META  655.26
-13.43 (-2.01%)
MSFT  400.75
-3.62 (-0.90%)
NVDA  189.76
-0.29 (-0.15%)
ORCL  156.07
-1.09 (-0.69%)
TSLA  425.69
-2.58 (-0.60%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.